Conference Coverage
Conference Coverage
‘Modest’ benefit for lecanemab in Alzheimer’s disease, but adverse events are common
The Food and Drug Administration is expected to make a decision about possible approval of the drug in January 2023.
Conference Coverage
Be aware, mindfulness training can lower systolic BP: MB-BP
“This is exactly what we need: a well-done trial with a control group to show that it actually works,” said one expert, cautioning that it...
Conference Coverage
Novel vaccine approach halts disease after 23 years of breast cancer
“The biggest impact so far for me has been that, for the first time in more than a decade, I am not on any medication. That’s really amazing.”
Conference Coverage
Optimize HF meds rapidly and fully after hospital discharge: STRONG-HF
Outcomes were superior with a high-intensity up-titration strategy compared with usual care, but questions about implementation in practice remain...
Conference Coverage
Tirzepatide cuts BP during obesity treatment
“The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term benefits of [tirzepatide] on...
Conference Coverage
First-line AFib ablation cuts risk of progression vs. drug therapy
Atrial fibrillation treated with ablation rather than drug therapy was less likely to progress to persistent symptoms in the PROGRESSIVE-AF trial...
Conference Coverage
Liver disease-related deaths rise during pandemic
“The increasing trend in mortality rates for ALD and NAFLD has been quite alarming, with disparities in age, race, and ethnicity.”
Conference Coverage
EHR-based thromboembolism risk tool boosted prophylaxis
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...
Conference Coverage
More evidence for EBV’s role in MS
Genetic sequencing of T-cell responses suggests the possibility of an ongoing immune response.
Conference Coverage
New trial suggests CV benefit with EPA: RESPECT-EPA
The open-label trial could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose...